Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.

@article{Ladenstein2013Ch1418AP,
  title={Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.},
  author={Ruth Ladenstein and Silke Weixler and Bianca Baykan and Matthias Bleeke and Renate E Kunert and Dietmar Katinger and Ingrid Pribill and Petra Glander and Steffen Bauer and Vito Pistoia and Jean Marie Michon and Alberto Garaventa and Holger N Lode},
  journal={mAbs},
  year={2013},
  volume={5 5},
  pages={801-9}
}
PURPOSE This study aimed to assess the safety, pharmacokinetic and activity profiles of the human-mouse chimeric monoclonal anti-disialoganglioside GD2 antibody ch14.18 produced in Chinese hamster ovary (CHO) cells (ch14.18/CHO). METHODS Sixteen children with recurrent/refractory neuroblastoma (median age 7.6 y) were enrolled in this Phase 1 dose-finding study. Patients received ch14.18/CHO courses of 10, 20 or 30 mg/m (2)/day as an eight-hour infusion over five consecutive days. Three… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Immunotherapy for Pediatric Malignancies

Springer International Publishing • 2018
View 20 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…